Session V: Pharmacology of β-Adrenoreceptor Blocking Drugs Chairman: Professor M.J. Rand (Melbourne)


, Volume 11, Supplement 1, pp 100-111

First online:

Some Aspects of the Pharmacology of β-Adrenoreceptor Blockers

  • B. ÅbladAffiliated withResearch Laboratories, AB Hassle, Fack
  • , E. CarlssonAffiliated withResearch Laboratories, AB Hassle, Fack
  • , C. DahlöfAffiliated withResearch Laboratories, AB Hassle, Fack
  • , L. EkAffiliated withResearch Laboratories, AB Hassle, Fack

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The pharmacodynamic properties of a β-blocker are mainly determined by its affinity to β1 andβ2-receptors respectively and by its intrinsic activity. It is suggested that there is no absolute organ separation of the two receptor sub-types. Instead bothβ1 andβ2 -receptors are involved in the mediation of the same effect. The frequency distribution ratio of β12-receptors varies markedly among various effector responses.

A non-selective and aβ1-selective blocker may have different haemodynamic effects when the levels of circulating adrenaline are high, because of their markedly different potency in inhibiting theβ2-mediated vasodilator effect of adrenaline. Data are presented which suggest the existence of a presynapticβ1 -receptor mediating a positive feedback mechanism on neuronal release of noradrenaline.